Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

Zymergen Inc ZY announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets. 

  • Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.
  • The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens. 
  • For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin. 
  • Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners. 
  • Zymergen will oversee all validation.
  • Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!